Click on the company or penalty amount for more information on each case. Click on the current parent name to reach the summary page for that parent company.
| Company | Current Parent | Current Parent Industry | Primary Offense Type  | Year | Agency | Penalty Amount |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $14,500,000 |
| Scios Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
| UCB Inc. | UCB | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $34,000,000 |
| Forest Pharmaceuticals Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
| Elan Corporation PLC | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
| Eisai Inc. | Eisai | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $11,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
| Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
| Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
| AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
| Warner Chilcott PLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
| Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | FDA | $36,000,000 |
| InterMune Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | FDA | $36,900,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | $71,000,000 |
| AstraZeneca | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | KY-AG | $5,500,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | $13,500,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2016 | MULTI-AG | $19,500,000 |
| Celgene Corp. | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,700,000 |
| Cephalon, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | CT-AG | $6,150,000 |
| Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | AR-AG | $18,500,000 |
| Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MS-AG | $18,500,000 |
| Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | LA-AG | $20,000,000 |
| Eli Lilly and Co. | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | CT-AG | $25,100,000 |
| Eli Lilly and Co. | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | ID-AG | $13,000,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $361,828,456 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $62,000,000 |
| Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | KY-AG | $3,700,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | KY-AG | $661,860 |
| Inspire Pharmaceuticals | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,000,000 |
| InterMune Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,700,000 |
| Janssen Ortho LLC and Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MT-AG | $5,900,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
| Novartis Pharmaceuticals | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | TX-AG | $6,638,250 |
| Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,681,516 |
| Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,500,000 |
| Pfizer | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $35,000,000 |
| Purdue Pharma | Purdue Pharma | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | MULTI-AG | $19,500,000 |
| Warner-Lambert | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $190,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
| Mallinckrodt, Inc. | Mallinckrodt | pharmaceuticals | nuclear safety violation | 2000 | NRC | $125,000 |
| CAMBRIDGE MAJOR LABORATORIES INC | Alcami | pharmaceuticals | motor vehicle safety violation | 2006 | FMCSA | $18,560 |
| EMD CHEMICALS INCORPORATED | Merck KGaA (EMD) | pharmaceuticals | motor vehicle safety violation | 2006 | FMCSA | $7,614 |
| CAMBRIDGE MAJOR LABORATORIES INC | Alcami | pharmaceuticals | motor vehicle safety violation | 2005 | FMCSA | $15,820 |
| EMD CHEMICALS INCORPORATED | Merck KGaA (EMD) | pharmaceuticals | motor vehicle safety violation | 2004 | FMCSA | $13,170 |
| Cody Laboratories Inc | Lannett Co. | pharmaceuticals | motor vehicle safety violation | 2018 | FMCSA | $8,510 |
| Actavis Kadian, LLC | AbbVie | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $116,703 |
| Intermune, Inc. | Roche | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $5,641 |
| Intermune, Inc. | Roche | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $16,215 |
| Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2015 | CMS | $5,909 |
| Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2015 | CMS | $9,440 |
| Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2016 | CMS | $10,788 |
| Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2016 | CMS | $12,367 |
| Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2019 | CMS | $12,968 |
| Wockhardt USA | Wockhardt Limited | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2020 | CMS | $111,824 |
| Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2023 | CMS | $31,959 |
| Parexel International, LLC | Parexel International | pharmaceuticals | labor relations violation | 2012 | NLRB | $253,000 |
| Amgen, Inc. | Amgen | pharmaceuticals | labor relations violation | 2011 | NLRB | $40,000 |
| Merck and Company, Inc. | Merck | pharmaceuticals | labor relations violation | 2009 | NLRB | $10,710 |
| Merck & Co., Inc. | Merck | pharmaceuticals | labor relations violation | 2008 | NLRB | $100,000 |
| Schering-Plough | Merck | pharmaceuticals | labor relations violation | 2007 | NLRB | $8,200 |
| Boehringer Ingelheim Pharmaceutical, Inc. | Boehringer Ingelheim | pharmaceuticals | labor relations violation | 2004 | NLRB | $50,000 |
| Advanced Medical Optics | Abbott Laboratories | pharmaceuticals | labor relations violation | 2004 | NLRB | $16,800 |
| Therasense, Inc. | Abbott Laboratories | pharmaceuticals | labor relations violation | 2003 | NLRB | $236,827 |
| St. Jude Medical Inc. | Abbott Laboratories | pharmaceuticals | kickbacks and bribery | 2011 | DOJ_CIVIL | $16,000,000 |
| Kos Pharmaceuticals | AbbVie | pharmaceuticals | kickbacks and bribery | 2010 | FDA | $41,500,000 |
| Novartis Pharmaceuticals | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | USAO | $390,000,000 |
| Novo Nordisk A/S | Novo Holdings A/S | pharmaceuticals | kickbacks and bribery | 2009 | DOJ_CRIMINAL | $9,000,000 |
| AstraZeneca PLC | AstraZeneca | pharmaceuticals | kickbacks and bribery | 2016 | SEC | $5,522,000 |
| GlaxoSmithKline plc | GlaxoSmithKline | pharmaceuticals | kickbacks and bribery | 2016 | SEC | $20,000,000 |
| Pharmacia & Upjohn Company Inc. | Pfizer | pharmaceuticals | kickbacks and bribery | 2007 | USAO | $19,700,000 |
| Pharmacia & Upjohn Company LLC | Pfizer | pharmaceuticals | kickbacks and bribery | 2007 | USAO | $15,000,000 |
| AbbVie Inc. | AbbVie | pharmaceuticals | kickbacks and bribery | 2018 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,800,000 |
| Alere Inc. | Abbott Laboratories | pharmaceuticals | kickbacks and bribery | 2017 | MS-AG | $2,000,000 |
| Kos Pharmaceuticals | AbbVie | pharmaceuticals | kickbacks and bribery | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,454,432 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $83,129,754 |
| Pfizer, Inc. | Pfizer | pharmaceuticals | kickbacks and bribery | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $331,485,170 |
| TAP Pharmaceutical Products, Inc. | Takeda Pharmaceutical | pharmaceuticals | kickbacks and bribery | 2006 | KY-AG | $600,000 |
| TAP Pharmaceutical Products, Inc. | Takeda Pharmaceutical | pharmaceuticals | kickbacks and bribery | 2006 | WI-AG | $798,000 |
| Teva Pharmaceuticals USA Inc. | Teva Pharmaceutical Industries | pharmaceuticals | kickbacks and bribery | 2014 | IL-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $12,100,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | kickbacks and bribery | 2016 | CA-INS | $30,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | kickbacks and bribery | 2020 | CA-AG | $11,800,000 |
| Novartis Pharmaceuticals Corp. | Novartis | pharmaceuticals | kickbacks and bribery | 2020 | MULTI-AG | $103,000,000 |
| Pacira Pharmaceuticals, Inc. | Pacira BioSciences | pharmaceuticals | kickbacks and bribery | 2020 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,500,000 |
| Schering-Plough Corporation | Merck | pharmaceuticals | investor protection violation | 2003 | SEC | $1,000,000 |
| Allergan Inc. | AbbVie | pharmaceuticals | investor protection violation | 2017 | SEC | $15,000,000 |
| Aegerion Pharmaceuticals | Amryt Pharma | pharmaceuticals | investor protection violation | 2017 | SEC | $4,100,000 |
| Cytrx Corporation | CytRx | pharmaceuticals | investor protection violation | 2017 | SEC | $75,000 |
| Clovis Oncology Inc. | Clovis Oncology | pharmaceuticals | investor protection violation | 2018 | SEC | $20,000,000 |
| Mylan N.V. | Viatris | pharmaceuticals | investor protection violation | 2019 | SEC | $30,000,000 |
| Amyris, Inc. | Amyris | pharmaceuticals | investor protection violation | 2021 | SEC | $300,000 |
| Valeant Pharmaceuticals, Inc. | Bausch Health | pharmaceuticals | insurance violation | 2018 | CA-INS | $1,875,000 |
| Johnson & Johnson, Inc. | Johnson & Johnson | pharmaceuticals | insurance violation | 2020 | NC-INS | $150,000 |
| Glenmark Pharmaceuticals, Inc. | Glenmark Pharmaceuticals | pharmaceuticals | HHS civil monetary penalties | 2015 | HHSOIG | $2,887,300 |
